In an attempt to address its upcoming revenue gap, Amgen has agreed to acquire Horizon Therapeutics for US$116.50 per share, representing an enterprise value of approximately US$28.3 B. Through the deal, Amgen picks up Horizon’s rare, autoimmune and severe inflammatory disease portfolio including thyroid eye disease drug, Tepezza® (teprotumumab-trbw) and gout treatment, Krystexxa® (pegloticase). The big pharma is on the hunt for new products as it prepares to face the looming patent cliffs of its top-selling drugs, including blockbuster arthritis drug, Enbrel® (etanercept).